Evidence map›Paper›PMID 37493965›Full record

ArticleNeurosurgical review2023

Survival in patients undergoing surgical resection for brain metastasis from lung cancer and utility of different prognostic scales.

Fábio Pires Botta, Lilian Aline Rocha, Vanessa das Graças Pereira de Souza, Patrícia Pintor Dos Reis, Estela de Oliveira Lima, Adriana Camargo Ferrasi, Adriano Yacubian Fernandes, Marco Antônio Zanini, Pedro Tadao Hamamoto Filho

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Neurosurgical review, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Fábio Pires BottaDepartment of Neurology, Psychology and Psychiatry, UNESP - São Paulo State University. Botucatu Medical School, Botucatu, Brazil.
Lilian Aline RochaClinics Hospital of Botucatu Medical School, Botucatu, Brazil.
Vanessa das Graças Pereira de SouzaDepartment of Surgery and Orthopedics, UNESP - São Paulo State University. Botucatu Medical School, Botucatu, Brazil.
Patrícia Pintor Dos ReisDepartment of Surgery and Orthopedics, UNESP - São Paulo State University. Botucatu Medical School, Botucatu, Brazil.
Estela de Oliveira LimaDepartment of Internal Medicine, UNESP - São Paulo State University, Botucatu Medical School, Botucatu, Brazil.
Adriana Camargo FerrasiDepartment of Internal Medicine, UNESP - São Paulo State University, Botucatu Medical School, Botucatu, Brazil.
Adriano Yacubian FernandesDepartment of Neurology, Psychology and Psychiatry, UNESP - São Paulo State University. Botucatu Medical School, Botucatu, Brazil.
Marco Antônio ZaniniDepartment of Neurology, Psychology and Psychiatry, UNESP - São Paulo State University. Botucatu Medical School, Botucatu, Brazil.
Pedro Tadao Hamamoto FilhoDepartment of Neurology, Psychology and Psychiatry, UNESP - São Paulo State University. Botucatu Medical School, Botucatu, Brazil. pedro.hamamoto@unesp.br.
Universidade Estadual Paulista (Unesp) · BRMedecell (Brazil) · BR

Funding

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior Finance Code 001
6 · The paper itself

Abstract

Brain metastases (BM) from lung cancer are among the most common intracranial tumors. Several studies have published scales to estimate the survival of patients with BM. Routine access to molecular diagnostics and modern oncologic treatments, including targeted therapy and immunotherapy, is limited in low- and middle-income countries (LMICs); therefore, incorporating them into recent prognostic scales may diminish the reliability of the scales in LMICs. This retrospective study aimed to determine the survival of 55 patients who were surgically treated for BM from lung cancer at a Brazilian public tertiary teaching hospital between 2012 and 2022. We determined clinical factors associated with survival, and compared observed survival rates with the estimated survival on prognostic scales. The mean overall survival (OS) was 9.3 months (range:0.2-76.5). At univariate analysis, female sex and improved postoperative Karnofsky performance status (KPS) score were associated with longer survival. The median survival did not differ between groups when classified using the Graded Prognostic Assessment (GPA)-2008, Lung-molecular GPA-2017, and Lung-GPA-2021 scales. According to the Diagnosis-Specific (DS)-GPA-2012 scale, there was a significant difference between the groups. In the multivariate Cox regression survival analysis, a higher DS-GPA-2012 and improved postoperative KPS score remained significantly associated with longer survival. In conclusion, this cohort showed a mean OS of < 1 year. Improved KPS score after surgery was associated with increased survival. This cohort DS-GPA scale demonstrated the highest concordance with observed survival, indicating its potential as a valuable tool for patient stratification in surgical treatment decision-making in LMICs.

Indexed as

Brain NeoplasmsLung NeoplasmsFemaleHumansPrognosisReproducibility of ResultsRetrospective StudiesBrain metastasisLung cancerPrognostic scoreSurgical resectionSurvival

Identifiers

PMID37493965
OpenAlexW4385264808

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.